Pds Biotechnology Stock Earnings Reports

PDS Biotech reported Q1 2026 progress focused on advancing clinical programs, with a key amendment to the VERSATILE-003 Phase III trial for PDS0101 (HPV16-positive head and neck cancer) to make progression-free survival (PFS) an interim co-primary endpoint to potentially enable accelerated approval, shorten trial duration and reduce costs while retaining overall survival for full approval. PDS0101 remains differentiated as a 5-dose, subcutaneous therapy given in combination with pembrolizumab (KEYTRUDA), and the company emphasized unmet need in HPV16-positive cancers. Encouraging clinical and biomarker data were reported for PDS01ADC (an IL-12 fused ADC) in colorectal cancer with liver metastases (JCO Oncology Advances publication) and in metastatic castration-resistant prostate cancer (NCI-led trial), supporting further development of the ADC program. The company strengthened intellectual property for PDS0101 with new U.S. and Japanese patents, extending market protection into the 2040s. Financially, Q1 net loss was $7.3 million ($0.13/share) versus $8.5 million year-over-year; R&D and G&A expenses declined. Cash on hand was $21.7 million as of March 31, 2026. Management highlighted that the VERSATILE-003 amendment reduces required enrollment (~350 to ~250 patients) and is expected to lower trial duration and costs, while manufacturing processes for Versamune are established and CMC validation work is planned in parallel with the Phase III.